There are no published human clinical trials of Dihexa, and the closest human evidence in its drug class Athira's fosgonimeton failed its Phase 3 Alzheimer's endpoint in 2024
Least Effective: Capsules Capsule forms of BPC157 are popular due to their convenience, but they have: Extremely low bioavailability Little to no peer-reviewed support Highly variable quality and dose accuracy These are not recommended for users seeking measurable healing or performance outcomes
Learn about this anti-aging peptide's research applications, quality standards, and sourcing tips for 2025.
Your physical therapist may use electrical modalities for this purpose such as ultrasound or electrical current
ProHealth Longevity BPC-157 emphasizes its single active compound, BPC-157, but questions remain about how it is formulated and whether it is supported by testing
TSA allows injectable medications through security with appropriate documentation